Literature DB >> 25493570

Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Edward D Esplin1, Ling Oei, Michael P Snyder.   

Abstract

The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advancements in interpretation of variants of unknown significance to maximize clinical benefit. Nevertheless, personalized sequencing, only recently applied to clinical medicine, has already been broadly applied to the discovery and study of disease. It is poised to enable the earlier and more accurate diagnosis of disease risk and occurrence, guide prevention and individualized intervention as well as facilitate monitoring of healthy and treated patients, and play a role in the prevention and recurrence of future disease. This article documents the advancing capacity of personalized sequencing, reviews its impact on disease-oriented scientific discovery and anticipates its role in the future of medicine.

Entities:  

Keywords:  cancer genomics; disease discovery; electronic medical record; genomic medicine; individualized therapy; next-generation sequencing; personalized medicine; pharmacogenetics; pharmacogenomics; precision medicine; prevention; whole-exome sequencing; whole-genome sequencing

Year:  2014        PMID: 25493570      PMCID: PMC4336568          DOI: 10.2217/pgs.14.117

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  90 in total

1.  A vision for the future of genomics research.

Authors:  Francis S Collins; Eric D Green; Alan E Guttmacher; Mark S Guyer
Journal:  Nature       Date:  2003-04-14       Impact factor: 49.962

Review 2.  Ancillary risk information and pharmacogenetic tests: social and policy implications.

Authors:  N B Henrikson; W Burke; D L Veenstra
Journal:  Pharmacogenomics J       Date:  2007-05-08       Impact factor: 3.550

3.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

4.  Personal genome sequencing: current approaches and challenges.

Authors:  Michael Snyder; Jiang Du; Mark Gerstein
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

Review 5.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 6.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

7.  An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus.

Authors:  Chirag J Patel; Jayanta Bhattacharya; Atul J Butte
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

8.  Clinical whole-exome sequencing: are we there yet?

Authors:  Paldeep Singh Atwal; Marie-Louise Brennan; Rachel Cox; Michael Niaki; Julia Platt; Margaret Homeyer; Andrea Kwan; Sylvie Parkin; Susan Schelley; Leah Slattery; Yael Wilnai; Jonathan Adam Bernstein; Gregory M Enns; Louanne Hudgins
Journal:  Genet Med       Date:  2014-02-13       Impact factor: 8.822

Review 9.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

Review 10.  Therapeutic potential of PARP inhibitors for metastatic breast cancer.

Authors:  Sheeba Irshad; Alan Ashworth; Andrew Tutt
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

View more
  15 in total

Review 1.  How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative.

Authors:  Fuki M Hisama; Junko Oshima; George M Martin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

2.  MOSClip: multi-omic and survival pathway analysis for the identification of survival associated gene and modules.

Authors:  Paolo Martini; Monica Chiogna; Enrica Calura; Chiara Romualdi
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

Review 3.  Defining the Clinical Value of a Genomic Diagnosis in the Era of Next-Generation Sequencing.

Authors:  Natasha T Strande; Jonathan S Berg
Journal:  Annu Rev Genomics Hum Genet       Date:  2016-05-26       Impact factor: 8.929

Review 4.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

5.  The Human Phenotype Ontology: Semantic Unification of Common and Rare Disease.

Authors:  Tudor Groza; Sebastian Köhler; Dawid Moldenhauer; Nicole Vasilevsky; Gareth Baynam; Tomasz Zemojtel; Lynn Marie Schriml; Warren Alden Kibbe; Paul N Schofield; Tim Beck; Drashtti Vasant; Anthony J Brookes; Andreas Zankl; Nicole L Washington; Christopher J Mungall; Suzanna E Lewis; Melissa A Haendel; Helen Parkinson; Peter N Robinson
Journal:  Am J Hum Genet       Date:  2015-06-25       Impact factor: 11.025

6.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.

Authors:  W S Bush; D R Crosslin; A Owusu-Obeng; J Wallace; B Almoguera; M A Basford; S J Bielinski; D S Carrell; J J Connolly; D Crawford; K F Doheny; C J Gallego; A S Gordon; B Keating; J Kirby; T Kitchner; S Manzi; A R Mejia; V Pan; C L Perry; J F Peterson; C A Prows; J Ralston; S A Scott; A Scrol; M Smith; S C Stallings; T Veldhuizen; W Wolf; S Volpi; K Wiley; R Li; T Manolio; E Bottinger; M H Brilliant; D Carey; R L Chisholm; C G Chute; J L Haines; H Hakonarson; J B Harley; I A Holm; I J Kullo; G P Jarvik; E B Larson; C A McCarty; M S Williams; J C Denny; L J Rasmussen-Torvik; D M Roden; M D Ritchie
Journal:  Clin Pharmacol Ther       Date:  2016-06-01       Impact factor: 6.875

7.  Large-Scale Low-Cost NGS Library Preparation Using a Robust Tn5 Purification and Tagmentation Protocol.

Authors:  Bianca P Hennig; Lars Velten; Ines Racke; Chelsea Szu Tu; Matthias Thoms; Vladimir Rybin; Hüseyin Besir; Kim Remans; Lars M Steinmetz
Journal:  G3 (Bethesda)       Date:  2018-01-04       Impact factor: 3.154

Review 8.  Aspects of Modern Biobank Activity - Comprehensive Review.

Authors:  Wiktor Paskal; Adriana M Paskal; Tomasz Dębski; Maciej Gryziak; Janusz Jaworowski
Journal:  Pathol Oncol Res       Date:  2018-05-05       Impact factor: 3.201

9.  Human Organic Anion Transporting Polypeptide 1B3 Applied as an MRI-Based Reporter Gene.

Authors:  Song Ee Baek; Asad Ul-Haq; Dae Hee Kim; Hyoung Wook Choi; Myeong Jin Kim; Hye Jin Choi; Honsoul Kim
Journal:  Korean J Radiol       Date:  2020-06       Impact factor: 3.500

10.  Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.

Authors:  J T Oates; D Lopez
Journal:  Int J Biomed Investig       Date:  2018-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.